Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Concurrent with IPO, ChemoCentryx privately raises $12mm from GSK and Techne

Executive Summary

At the same time it closed its $41.8mm IPO, ChemoCentryx Inc. (treatments for autoimmune disease, inflammation, and cancer that target the chemokine system) raised $12mm by selling common stock to GlaxoSmithKline PLC and Techne Corp., both existing shareholders, in concurrent private placements. GSK (which had initially acquired a $25mm equity stake in 2006 when the companies partnered on inflammation targets) bought 700k shares while Techne (which first acquired stock in a 1997 agreement) purchased 500k shares, all at the $10 IPO price. GSK and Techne now own 21.7% and 18.3% stakes, respectively, in ChemoCentryx.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies